Alterity Therapeutics (ATHE) Competitors $2.20 +0.10 (+4.76%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends ATHE vs. SLS, CUE, ONCY, BYSI, VNRX, ATRA, SPRO, CNTB, MURA, and IVVDShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include SELLAS Life Sciences Group (SLS), Cue Biopharma (CUE), Oncolytics Biotech (ONCY), BeyondSpring (BYSI), VolitionRx (VNRX), Atara Biotherapeutics (ATRA), Spero Therapeutics (SPRO), Connect Biopharma (CNTB), Mural Oncology (MURA), and Invivyd (IVVD). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. SELLAS Life Sciences Group Cue Biopharma Oncolytics Biotech BeyondSpring VolitionRx Atara Biotherapeutics Spero Therapeutics Connect Biopharma Mural Oncology Invivyd Alterity Therapeutics (NASDAQ:ATHE) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Does the MarketBeat Community believe in ATHE or SLS? SELLAS Life Sciences Group received 6 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Alterity Therapeutics an outperform vote while only 55.56% of users gave SELLAS Life Sciences Group an outperform vote. CompanyUnderperformOutperformAlterity TherapeuticsOutperform Votes466.67% Underperform Votes233.33% SELLAS Life Sciences GroupOutperform Votes1055.56% Underperform Votes844.44% Do analysts rate ATHE or SLS? Alterity Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 172.73%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Alterity Therapeutics is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, ATHE or SLS? Alterity Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500. Is ATHE or SLS more profitable? Alterity Therapeutics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A SELLAS Life Sciences Group N/A -629.46%-178.65% Do insiders and institutionals hold more shares of ATHE or SLS? 2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 1.2% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor ATHE or SLS? In the previous week, Alterity Therapeutics had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 1 mentions for Alterity Therapeutics and 0 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.23 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Overall Sentiment Alterity Therapeutics Neutral SELLAS Life Sciences Group Neutral Which has stronger earnings & valuation, ATHE or SLS? Alterity Therapeutics has higher earnings, but lower revenue than SELLAS Life Sciences Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/ASELLAS Life Sciences Group$1M62.50-$37.34M-$0.69-1.29 SummaryAlterity Therapeutics beats SELLAS Life Sciences Group on 9 of the 14 factors compared between the two stocks. Ad Investors AlleyCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…Click here to discover the new #1 way to invest in Tesla Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.07M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5589.7417.16Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book1.775.094.784.78Net Income-$12.54M$151.83M$120.31M$225.60M7 Day Performance-8.33%-2.14%-1.92%-1.23%1 Month Performance105.61%-4.56%13.65%0.46%1 Year Performance-17.60%8.87%28.34%15.24% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics2.5796 of 5 stars$2.20+4.8%$6.00+172.7%-15.4%$16.07MN/A0.0010News CoverageSLSSELLAS Life Sciences Group0.0104 of 5 stars$0.93+7.1%N/A-22.8%$65.74M$1M-1.3916CUECue Biopharma4.6871 of 5 stars$1.03+9.6%$5.00+385.4%-64.2%$65.25M$9.53M-1.0360News CoveragePositive NewsONCYOncolytics Biotech1.912 of 5 stars$0.82+1.2%$4.00+386.0%-33.5%$63.43MN/A-3.0030News CoverageBYSIBeyondSpringN/A$1.62-1.2%N/A+76.7%$63.23M$1.88M0.0080Positive NewsGap DownVNRXVolitionRx1.7482 of 5 stars$0.66+15.9%$3.75+472.5%+4.3%$60.70M$770,000.00-1.5780Analyst ForecastGap UpATRAAtara Biotherapeutics3.8395 of 5 stars$10.38+0.5%$16.67+60.6%+2.3%$59.79M$100.44M-0.40165Analyst ForecastNews CoverageGap UpSPROSpero Therapeutics4.5428 of 5 stars$1.10+2.3%$5.00+356.6%-29.8%$59.70M$103.78M15.2946Analyst DowngradeNews CoverageCNTBConnect Biopharma3.4776 of 5 stars$1.08-3.4%$8.00+640.7%+14.5%$59.68M$24.12M0.00110Positive NewsGap DownMURAMural Oncology3.0875 of 5 stars$3.45-5.2%$16.00+363.8%-13.1%$58.72MN/A-0.40119IVVDInvivyd3.783 of 5 stars$0.49-10.7%$7.89+1,515.0%-88.2%$58.42M$11.56M-0.28100News CoverageGap Down Related Companies and Tools Related Companies SLS Competitors CUE Competitors ONCY Competitors BYSI Competitors VNRX Competitors ATRA Competitors SPRO Competitors CNTB Competitors MURA Competitors IVVD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATHE) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
